CSIMarket Company Name, Ticker, Customers, else..
 
Rhythm Pharmaceuticals Inc   (NASDAQ: RYTM)
 
Price: $106.1300 $-1.04 -0.970%
Day's High: $108.84500122070312 Week Perf: -6.37 %
Day's Low: $ 103.98 30 Day Perf: 6.93 %
Volume (M): 678,952 52 Wk High: $ 122.20
Volume (M$): $ 0 52 Wk Avg: $100.15
Open: $106.01 52 Wk Low: $74.50



 Market Capitalization (Millions $) 7,280
 Shares Outstanding (Millions) 69
 Employees 414
 Revenues (TTM) (Millions $) 240
 Net Income (TTM) (Millions $) -210
 Cash Flow (TTM) (Millions $) -73
 Capital Exp. (TTM) (Millions $) 41

Business Description


Rhythm Pharmaceuticals Inc. is a biopharmaceutical company that focuses on developing therapies for rare genetic disorders of obesity. The company is committed to addressing the unmet medical needs of patients with these conditions and aims to improve their quality of life. Rhythm Pharmaceuticals utilizes a precision medicine approach to develop innovative therapies that target specific genetic mutations causing obesity-related disorders. Their research and development efforts are centered around a pipeline of potential treatments that aim to restore metabolic balance and help patients achieve sustainable weight loss and improvement in their overall health.


   Company Address: 222 Berkeley Street Boston 2116 MA
   Company Phone Number: 264-4280   Stock Exchange / Ticker: NASDAQ RYTM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
HRTX   -0.63%    
LGND        1.4% 
MGNX   -0.75%    
NRIX   -1.87%    
SNDX   -1.43%    
TEVA   -2.38%    
• View Complete Report
   



Partnership

Rhythm Pharmaceuticals Joins Forces with Raymond A. Wood Foundation to Launch Groundbreaking Research on Craniopharyn...

Published Tue, Mar 18 2025 11:57 AM UTC

In a significant stride towards understanding and addressing the debilitating impacts of fatigue in patients with craniopharyngioma, Rhythm Pharmaceuticals, a biopharmaceutical company focused on innovative therapies for rare neurological diseases, has announced a research collaboration with the Raymond A. Wood Foundation. This partnership aims to establish a comprehensive r...
Management Announcement

Rhythm Pharmaceuticals: Transformative FDA Approval Sparks Hope Amidst Revenue Challenges and Strategic Innovations,

Published Fri, Jan 10 2025 12:15 PM UTC

Rhythm Pharmaceuticals: Navigating Growth Amidst Challenges and BreakthroughsRhythm Pharmaceuticals, Inc. has made significant strides and faced notable challenges in 2024, as articulated in their preliminary financial announcements and recent FDA developments. This article aims to dissect the key facts surrounding the company s performance, product approvals, and its futu...
Management Announcement

Rhythm Pharmaceuticals IMCIVREE Receives FDA Approval for Pediatric Use Amidst Declining Revenue Concerns

Published Fri, Dec 20 2024 7:15 PM UTC

Rhythm Pharmaceuticals’ New Milestone: A Beacon of Hope or a Signal of Trouble?BOSTON, Dec. 20, 2024 – In a significant move that underscores the urgency in treating rare genetic disorders, Rhythm Pharmaceuticals, Inc. has officially announced FDA approval for its groundbreaking drug, IMCIVREE (setmelanotide), for patients as young as two years old. This approval extend...
Clinical Study

Rhythm Pharmaceuticals Breaks New Ground Expanded UK Authorization for IMCIVREE and Promising Clinical Fin...

Published Tue, Dec 3 2024 11:00 AM UTC

Rhythm Pharmaceuticals, Inc. a biopharmaceutical company headquartered in Boston and traded on Nasdaq under the ticker RYTM, has announced an expanded marketing authorization for its drug, IMCIVREE (setmelanotide), in the United Kingdom. The United Kingdom s Medicines & Healthcare products Regulatory Agency (MHRA) has now sanctioned the use of IMCIVREE for treating obesity a...
Clinical Study

Rhythm Pharmaceuticals Reveals Promising Data at ESPE 2024 A New Dawn in Fighting Hypothalamic Obesity

Published Mon, Nov 18 2024 12:00 PM UTC

In an exciting announcement, Rhythm Pharmaceuticals has unveiled five impactful presentations at the upcoming European Society for Paediatric Endocrinology (ESPE) 2024, focusing on real-world data and therapeutic advancements related to setmelanotide. The data, particularly spotlighting pediatric patients with acquired or congenital hypothalamic obesity, offers a glimpse int...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 30.34
Price to Sales (Expected) -
Price to Book 70.69
PEG (TTM) -

Financial Strength Current
Quick Ratio 20.65
Working Capital Ratio 23.99
Leverage Ratio (MRQ) 3.25
Total Debt to Equity 1.03
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.05 $
Revenues (TTM) 3.5 $
Cash Flow (TTM) -
Cash 8.69 $
Book Value 1.5 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 579,512
Net Income per Employee (TTM) -507,783
Receivable Turnover Ratio (TTM) 7.18
Inventory Turnover Ratio (TTM) 0.99
Asset Turnover Ratio (TTM) 0.45

Profitability Ratios Current
Gross Margin (MRQ) 87.47 %
Operating Margin (MRQ) -68.14 %
Net Margin (MRQ) -70.68 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Rhythm Pharmaceuticals Inc's Segments
Product    184.36 % of total Revenue
Single Reportable    184.36 % of total Revenue
United States    123.34 % of total Revenue
Non-US    61.03 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.